| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/22/2011 | US7893252 Selectively depolymerized galactomannan polysaccharide |
| 02/22/2011 | US7893245 Interfering RNA molecules |
| 02/22/2011 | US7893242 Oligonucleotide compositions and their use to induce apoptosis |
| 02/22/2011 | US7893240 High level expression of recombinant human erythropoietin having a modified 5′-UTR |
| 02/22/2011 | US7893226 Use of lipid conjugates in the treatment of diseases |
| 02/22/2011 | US7893217 Isolated human antibodies that bind epitopes on RG1 |
| 02/22/2011 | US7893215 Agonist antibodies to IL-23 receptor |
| 02/22/2011 | US7893213 Antibodies to activin receptor |
| 02/22/2011 | US7893211 Polypeptide fusion comprising three nonoverlapping domains for use as tool in identifying modulator for enhancing immune response; immunization; |
| 02/22/2011 | US7893204 Attractin/mahogany-like polypeptides |
| 02/22/2011 | US7893202 Post-translational modifications and Clostridial neurotoxins |
| 02/22/2011 | US7893200 Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases |
| 02/22/2011 | US7893199 Peptides having neutrophil-stimulating activity |
| 02/22/2011 | US7893197 Relaxin-3 chimeric polypeptides and their preparation and use |
| 02/22/2011 | US7893196 Polypeptides having antimicrobial activity and polynucleotides encoding same |
| 02/22/2011 | US7893113 Materials and methods for modulating metabolism |
| 02/22/2011 | US7893084 Viral polymerase inhibitors |
| 02/22/2011 | US7893041 Oligosaccharide compositions and use thereof in the treatment of infection |
| 02/22/2011 | US7893033 Targeting proteins to deliver therapeutic or diagnostic reagents |
| 02/22/2011 | US7893032 NgR variants and compositions thereof for suppressing axonal growth inhibition |
| 02/22/2011 | US7893031 Neuronal differentiation inhibitor peptide and use thereof |
| 02/22/2011 | US7893030 Stable chromogenic test reagent and its use in coagulation-diagnostic tests |
| 02/22/2011 | US7893029 Recombinant lubricin molecules and uses thereof |
| 02/22/2011 | US7893028 Isolated mutant protein of fibroblast growth factor 18 and pharmaceutical composition comprising the same |
| 02/22/2011 | US7893027 Treatment of ocular wounds and ulcers |
| 02/22/2011 | US7893026 Treatment of EGFR-dependent tumors by ABIN (a20 -binding inhibitor of NF kappab) |
| 02/22/2011 | US7893025 Use of growth hormone releasing factor analogs in treating patients suffering from wasting |
| 02/22/2011 | US7893024 Enhancement of iron chelation therapy |
| 02/22/2011 | US7893023 Prodrugs activated by plasmin and their use in cancer chemotherapy |
| 02/22/2011 | US7893022 Anti-angiogenic methods and compositions |
| 02/22/2011 | US7893021 Parathyroid hormone antagonists and uses thereof |
| 02/22/2011 | US7893020 can be coadministered with antimicrobial agents for treatment of infections caused by drug resistant bacteria; 2-Amino-N-{4-Amino-1-[-3-phenyl-1-(R)-(quinolin-3-ylcarbomoyl)-propylcarbamoyl]-butyl}succinamic acid; 2,5-Diamino-pentanoic acid [3-phenyl-1-(R)-(4-phenyl-thiazol-2-ylcarbamoyl)-propyl]-amide |
| 02/22/2011 | US7893019 G-CSF site-specific mono-conjugates |
| 02/22/2011 | US7893018 Method of treatment for ischemic heart disease |
| 02/22/2011 | US7893017 Protracted GLP-1 compounds |
| 02/22/2011 | US7893016 Stabilisation of double-stranded nucleic acids using proteins |
| 02/22/2011 | US7893007 Directed evolution of novel binding proteins |
| 02/22/2011 | US7892834 Cellular signal-responsive gene transcriptional regulation system |
| 02/22/2011 | US7892828 Method of identifying a MHC class I restricted T cell response |
| 02/22/2011 | US7892793 Allele-specific RNA interference |
| 02/22/2011 | US7892773 Expression vector comprising nucleotide sequences coding homeobox transcriptional regulator gene for identifying modulators for treatment and prevention of cell proliferative disorders of urogenital system |
| 02/22/2011 | US7892755 Of nitroquinoxaline-2,3-diones or ellagic acid as binding ligands for G protein coupled receptor 35; antidiabetic agents; anticarcinogenic agents for gastrointestinal cancer; obesity, immunotherapy |
| 02/22/2011 | US7892754 Hepatitis B virus pre-S1 derived synthetic polypeptides and uses thereof |
| 02/22/2011 | US7892727 Chemokine-binding protein and methods of use |
| 02/22/2011 | US7892572 Orthopaedic materials derived from keratin |
| 02/22/2011 | US7892563 Methods for treatment of severe acute respiratory syndrome (SARS) |
| 02/22/2011 | US7892561 Neutralizing GDF8 epitope-based growth enhancing vaccine |
| 02/22/2011 | US7892560 Clostridial toxin derivatives able to modify peripheral sensory afferent functions |
| 02/22/2011 | US7892559 Major histocompatibility complex class I restricted epitope peptide for use in diagnosis, prevention and treament of cell proliferative disorders; antitumor agents |
| 02/22/2011 | US7892558 Isolated TNF-alpha peptide and pharmaceutical composition thereof |
| 02/22/2011 | US7892557 Peptide mimotopes of mycobacterial mannosylated lipoglycans and uses thereof |
| 02/22/2011 | US7892556 Apoptotically active peptides |
| 02/22/2011 | US7892554 Using immunoglobulin fusion to deliver effector cells; tissue targeted therapy; antitumor agents |
| 02/22/2011 | US7892549 Treatment with anti-ErbB2 antibodies |
| 02/22/2011 | US7892548 121P1F1: a tissue specific protein highly expressed in various cancers |
| 02/22/2011 | US7892547 Methods and compositions for administering therapeutic and diagnostic agents |
| 02/22/2011 | US7892543 Chimeric antibodies; lymphocytes; genetic engineering; for treatment of myeloma |
| 02/22/2011 | US7892539 Modulation of an innate immune response by altering TRIAL-R signaling |
| 02/22/2011 | US7892537 High activity mutants of butyrylcholinesterase for cocaine hydrolysis |
| 02/22/2011 | US7892536 Storage-stable glucose oxidase |
| 02/22/2011 | US7892532 Intracellular delivery of osteoinductive proteins and peptides |
| 02/22/2011 | US7892531 Human serum albumin(HSA); solubilized in low-ionic-strength buffer with specified ph; glycine, aspartic acid, sodium succinate, trehalose; binds with receptors |
| 02/22/2011 | US7892530 Treatment of tumor metastases and cancer |
| 02/22/2011 | US7892529 Peptides for active anti-cytokine immunization |
| 02/22/2011 | CA2609667C Human proislet peptide, derivatives and analogs thereof, and methods of using same |
| 02/22/2011 | CA2583823C Platelet-derived growth factor compositions and methods of use thereof |
| 02/22/2011 | CA2554195C Peptide originating in epidermal growth factor receptor (egfr) |
| 02/22/2011 | CA2540678C Pharmaceutical compositions for prevention of overdose or abuse |
| 02/22/2011 | CA2472093C Use of sulfated glycosaminoglycans for establishing effective labor in women |
| 02/22/2011 | CA2470564C Recombinant polypeptides |
| 02/22/2011 | CA2441566C Blood cell production via activation of the hemoglobin scavenger receptor |
| 02/22/2011 | CA2435877C Prevention of diabetes by administration of gnrh antagonists |
| 02/22/2011 | CA2435503C Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy |
| 02/22/2011 | CA2432289C Interleukin-18 inducer |
| 02/22/2011 | CA2410193C Neuronal serine-threonine protein kinase |
| 02/22/2011 | CA2392685C Antisense antibacterial method and composition |
| 02/22/2011 | CA2329772C Artificial t helper cell epitopes as immune stimulators for synthetic peptide immunogens |
| 02/22/2011 | CA2185998C The combination of growth hormone and insulin-like growth factor, for treating congestive heart failure |
| 02/22/2011 | CA2143491C A novel peptide related to human programmed cell death and dna encoding it |
| 02/22/2011 | CA2137221C Preparation of 3,4,4-trisubstituted piperidinyl-n-alkylcarboxylates and intermediates |
| 02/17/2011 | WO2011020117A2 Methods of treating cancer using neurotrophin retargeted endopeptidases |
| 02/17/2011 | WO2011020115A2 Methods of treating cancer using growth factor retargeted endopeptidases |
| 02/17/2011 | WO2011020114A2 Methods of treating cancer using tachykinin retargeted endopeptidases |
| 02/17/2011 | WO2011020091A1 Modified vasoactive intestinal peptides |
| 02/17/2011 | WO2011020090A2 Compositions and methods for treating cancer |
| 02/17/2011 | WO2011020079A1 Antibodies against human respiratory syncytial virus (rsv) and methods of use |
| 02/17/2011 | WO2011020056A2 Methods of treating cancer using galanin retargeted endpeptidases |
| 02/17/2011 | WO2011020054A1 Method for modulating the pharmacodynamic effect of orally administered guanylate cyclase receptor agonists |
| 02/17/2011 | WO2011020047A1 Use of il-15 to increase thymic output and to treat lymphopenia |
| 02/17/2011 | WO2011020045A1 Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels |
| 02/17/2011 | WO2011020033A2 Engineered proteins including mutant fibronectin domains |
| 02/17/2011 | WO2011019963A2 Prg4 treatment for interstitial cystitis |
| 02/17/2011 | WO2011019839A2 Glycopeptide and lipoglycopeptide antibiotics with improved solubility |
| 02/17/2011 | WO2011019819A1 Orally disintegrating compositions of linaclotide |
| 02/17/2011 | WO2011019809A1 Methods for preventing or treating metabolic syndrome |
| 02/17/2011 | WO2011019801A1 Cathepsin c inhibitors |
| 02/17/2011 | WO2011019285A1 Separation and/or purification of pneumocandin b0 from c0 |
| 02/17/2011 | WO2011019221A2 Agent for stimulating mobilization of endothelial progenitor cells |
| 02/17/2011 | WO2011019123A1 Novel peptide and use thereof |
| 02/17/2011 | WO2011019081A1 Light-receiving channel rhodopsin having improved expression efficiency |